Replimune Group (REPL) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

REPL Stock Forecast

Replimune Group stock forecast is as follows: an average price target of $24.20 (represents a 115.49% upside from REPL’s last price of $11.23) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

REPL Price Target

The average price target for Replimune Group (REPL) is $24.20 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $43.00 to $13.00. This represents a potential 115.49% upside from REPL's last price of $11.23.

REPL Analyst Ratings

Buy

According to 6 Wall Street analysts, Replimune Group's rating consensus is 'Buy'. The analyst rating breakdown for REPL stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Replimune Group Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 07, 2024	Robert Burns	H.C. Wainwright	$17.00	$7.11	139.10%	51.38%
Jun 04, 2024	Peter Lawson	Barclays	$13.00	$5.37	142.09%	15.76%
May 17, 2024	Evan Seigerman	BMO Capital	$14.00	$6.85	104.38%	24.67%
Dec 12, 2022	-	BMO Capital	$70.00	$25.00	180.00%	523.33%
Dec 07, 2022	-	Leerink Partners	$34.00	$23.09	47.25%	202.76%
Oct 03, 2022	-	Leerink Partners	$30.00	$17.27	73.71%	167.14%
Aug 17, 2022	-	Piper Sandler	$43.00	$20.62	108.54%	282.90%
Aug 05, 2022	-	Leerink Partners	$37.00	$20.37	81.64%	229.47%
May 20, 2022	-	Leerink Partners	$48.00	$14.38	233.80%	327.43%

Row per page

Go to

The latest Replimune Group stock forecast, released on Jun 07, 2024 by Robert Burns from H.C. Wainwright, set a price target of $17.00, which represents a 139.10% increase from the stock price at the time of the forecast ($7.11), and a 51.38% increase from REPL last price ($11.23).

Replimune Group Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	3
Avg Price Target	-	-	$14.67
Last Closing Price	$11.23	$11.23	$11.23
Upside/Downside	-100.00%	-100.00%	30.63%

In the current month, the average price target of Replimune Group stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Replimune Group's last price of $11.23. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 10, 2024	BMO Capital	Outperform	Outperform	Hold
Sep 10, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 08, 2024	Rodman & Renshaw	-	Buy	Initialise
Jun 07, 2024	BMO Capital	Outperform	Outperform	Hold
Jun 07, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 04, 2024	Barclays	Overweight	Overweight	Hold
May 17, 2024	BMO Capital	Outperform	Outperform	Hold
Dec 06, 2023	Barclays	Overweight	Overweight	Hold
Dec 12, 2022	BMO Capital	Outperform	Outperform	Hold
Dec 07, 2022	SVB Leerink	Outperform	Outperform	Hold

Row per page

Go to

Replimune Group's last stock rating was published by BMO Capital on Sep 10, 2024. The company gave REPL a "Outperform" rating, the same as its previous rate.

Replimune Group Financial Forecast

Replimune Group Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$120.08M	$114.44M	$107.40M	$100.33M	$96.30M	$89.89M	$82.56M	$76.24M	$70.73M	$64.51M	$57.91M	$25.05M	$17.60M	$22.65M	$15.37M	$5.56M	-	-	-
High Forecast	$120.08M	$114.44M	$107.40M	$100.33M	$96.30M	$89.89M	$82.56M	$76.24M	$70.73M	$64.51M	$57.91M	$25.05M	$17.60M	$22.65M	$15.37M	$5.56M	-	-	-
Low Forecast	$120.08M	$114.44M	$107.40M	$100.33M	$96.30M	$89.89M	$82.56M	$76.24M	$70.73M	$64.51M	$57.91M	$25.05M	$17.60M	$22.65M	$15.37M	$5.56M	-	-	-
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Replimune Group's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. REPL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Replimune Group EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict REPL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Replimune Group's previous annual EBITDA (undefined) of $NaN.

Replimune Group Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-	-	-
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-11.09M	$-13.67M	$-17.13M	$-20.62M	$-22.24M	$-25.35M	$-29.05M	$-32.13M	$-34.73M	$-37.78M	$-41.29M	$-53.82M	$-55.00M	$-64.43M	$-66.78M	$-58.67M	$-59.83M	$-64.69M	$-59.29M
High Forecast	$-11.09M	$-13.67M	$-17.13M	$-20.62M	$-22.24M	$-25.35M	$-29.05M	$-32.13M	$-34.73M	$-37.78M	$-41.29M	$-53.82M	$-55.00M	$-64.43M	$-66.78M	$-53.05M	$-55.73M	$-64.69M	$-59.29M
Low Forecast	$-11.09M	$-13.67M	$-17.13M	$-20.62M	$-22.24M	$-25.35M	$-29.05M	$-32.13M	$-34.73M	$-37.78M	$-41.29M	$-53.82M	$-55.00M	$-64.43M	$-66.78M	$-65.91M	$-63.92M	$-64.69M	$-59.29M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Replimune Group's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. REPL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Replimune Group SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-	-	-
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Replimune Group's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to REPL last annual SG&A of $NaN (undefined).

Replimune Group EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-0.14	$-0.17	$-0.22	$-0.26	$-0.28	$-0.32	$-0.37	$-0.41	$-0.44	$-0.48	$-0.53	$-0.69	$-0.70	$-0.82	$-0.85	$-0.75	$-0.76	$-0.82	$-0.86
High Forecast	$-0.14	$-0.17	$-0.22	$-0.26	$-0.28	$-0.32	$-0.37	$-0.41	$-0.44	$-0.48	$-0.53	$-0.69	$-0.70	$-0.82	$-0.85	$-0.68	$-0.71	$-0.82	$-0.86
Low Forecast	$-0.14	$-0.17	$-0.22	$-0.26	$-0.28	$-0.32	$-0.37	$-0.41	$-0.44	$-0.48	$-0.53	$-0.69	$-0.70	$-0.82	$-0.85	$-0.84	$-0.81	$-0.82	$-0.86
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Replimune Group's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to REPL previous annual EPS of $NaN (undefined).

Replimune Group Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VTYX	Ventyx Biosciences	$1.72	$33.86	1868.60%	Buy
GOSS	Gossamer Bio	$0.70	$3.75	435.71%	Buy
AVTE	Aerovate Therapeutics	$2.66	$13.00	388.72%	Hold
LYRA	Lyra Therapeutics	$0.18	$0.50	177.78%	Hold
PRTC	PureTech Health	$21.70	$57.00	162.67%	Buy
MLYS	Mineralys Therapeutics	$12.60	$30.00	138.10%	Buy
REPL	Replimune Group	$11.23	$24.20	115.49%	Buy
SNDX	Syndax Pharmaceuticals	$15.95	$34.30	115.05%	Buy
KRON	Kronos Bio	$0.86	$1.63	89.53%	Buy
KROS	Keros Therapeutics	$54.14	$102.60	89.51%	Buy
NAMS	NewAmsterdam Pharma Company	$20.01	$36.50	82.41%	Buy
MRUS	Merus	$42.93	$77.13	79.66%	Buy
KURA	Kura Oncology	$15.91	$26.00	63.42%	Buy
ASND	Ascendis Pharma	$124.38	$190.21	52.93%	Buy
CRNX	Crinetics Pharmaceuticals	$56.07	$70.14	25.09%	Buy
PTGX	Protagonist Therapeutics	$40.65	$50.00	23.00%	Buy
NUVL	Nuvalent	$91.17	$111.57	22.38%	Buy
UTHR	United Therapeutics	$364.33	$358.20	-1.68%	Buy
CERE	Cerevel Therapeutics	$44.96	$33.50	-25.49%	Buy

REPL Forecast FAQ

Is Replimune Group a good buy?

Yes, according to 6 Wall Street analysts, Replimune Group (REPL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of REPL's total ratings.

What is REPL's price target?

Replimune Group (REPL) average price target is $24.2 with a range of $13 to $43, implying a 115.49% from its last price of $11.23. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Replimune Group stock go up soon?

According to Wall Street analysts' prediction for REPL stock, the company can go up by 115.49% (from the last price of $11.23 to the average price target of $24.2), up by 282.90% based on the highest stock price target, and up by 15.76% based on the lowest stock price target.

Can Replimune Group stock reach $20?

REPL's average twelve months analyst stock price target of $24.2 supports the claim that Replimune Group can reach $20 in the near future.

What are Replimune Group's analysts' financial forecasts?

Replimune Group's analysts financial forecasts for the fiscal year (Mar 2027) are as follows: average revenue is $269.38M (high $269.38M, low $269.38M), average EBITDA is $0 (high $0, low $0), average net income is $-146M (high $-146M, low $-146M), average SG&A $0 (high $0, low $0), and average EPS is $-1.857 (high $-1.857, low $-1.857). REPL's analysts financial forecasts for the fiscal year (Mar 2028) are as follows: average revenue is $369.07M (high $369.07M, low $369.07M), average EBITDA is $0 (high $0, low $0), average net income is $-97.246M (high $-97.246M, low $-97.246M), average SG&A $0 (high $0, low $0), and average EPS is $-1.238 (high $-1.238, low $-1.238).